Loading...
•
Mar 31, 2022
Sorrento Q1 2022 Earnings Report
Reported continuous sales growth in ZTlido.
Key Takeaways
Scilex Holding Company reported preliminary gross sales of approximately $18.4 million for ZTlido in 1Q2022, representing a 26% growth compared to 1Q2021.
Preliminary gross sales for ZTlido in 1Q2022 were approximately $18.4 million.
ZTlido sales in 1Q2022 grew by 26% compared to 1Q2021.
March 2022 ZTlido sales were $8.1 million, a 53% increase year-over-year.
Scilex is focused on expanding payor coverage for ZTlido as a first-line therapy for neuropathic pain.
Revenue by Segment
Forward Guidance
Scilex Holding Company and Vickers Vantage Corp. I entered into a definitive business combination agreement on March 17, 2022, with the closing expected by the third quarter of 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...